Vivo Capital IX, LLC 3
3 · Tarsus Pharmaceuticals, Inc. · Filed Oct 15, 2020
Insider Transaction Report
Form 3
Vivo Capital IX, LLC
10% Owner
Holdings
Series C Preferred Stock
→ Common Stock (214,281 underlying)Series B Preferred Stock
→ Common Stock (2,780,754 underlying)
Footnotes (3)
- [F1]The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F2]The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.
- [F3]The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.